Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART (CLEAR)

This study has been completed.
Sponsor:
Collaborators:
Massachusetts General Hospital
Monash University
University of Sydney
Novartis
Aarhus University Hospital
Information provided by (Responsible Party):
University of Aarhus
ClinicalTrials.gov Identifier:
NCT01680094
First received: September 3, 2012
Last updated: February 24, 2014
Last verified: February 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2014
  Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)